 scope of the present invention provided that the features of any such combination are not mutually inconsistent.
These and other aspects and advantages of the present invention are set forth in the following detailed description and Examples and claims.
The present compositions comprise quinolone components, NSAID components and carrier components.
Preferably, the present quinolone components exhibit fungistatic properties in the present compositions. That is, the quinolone components in the present compositions preferably are effective to preserve the present compositions against population growth of fungi, such as C. Albicans and A. niger. 
The fungistatic activity or properties of the present quinolone components provide added protection against microbial, for example, fungal, contamination of the present compositions. Such fungistatic activity can result in reducing the concentration of added preservative components in the present compositions, thereby reducing the risk of irritation and/or other uncomfortable side effects caused by the presence of such added preservatives. Even if the present compositions are substantially free of added preservative components, it has been found that many of the present compositions have sufficient preservative efficacy to meet or exceed the standards of the United States Preservative Efficacy Test (USPET).
The present compositions include quinolone components. A number of such quinolone components are known and have been used for many years in antibiotic applications. For example, nalidixic acid has been available for the treatment of urinary tract infections. The useful quinolone components preferably are four-quinolones that contain a carboxylic moiety in the three position of the basic structure shown below: 
The present quinolone components preferably are halogenated. For example, a chlorinated quinolone component, such as 9-chloro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-2,3-dihydro-7H-pyridol[1,2,3-de][1,4]benzozaxine-6 carboxylic acid may be used.
More preferably, the present quinolone components are fluorinated. Examples of such fluorinated quinolones include norfloxacin, ciprofloxacin and ofloxacin. Such fluorinated quinolone components are highly effective against a range of bacteria and are useful in treating various microbial infections in the mammalian eye. Prior ofloxacin-containing compositions including such quinolone used for this purpose include additional preservatives, for example, BAK.
It has been found
scope of the present invention provided that the features of any such combination are not mutually inconsistent. 
 These and early view and advantages of the present invention are set forth in the follow detailed description and model and claims. 
 The present compositions consist quinolone components, NSAID components and aircraft carrier components. 
 Preferably, the present quinolone components parade fungistatic properties in the present compositions. That is, the quinolone component in the present compositions preferably are effective to preserve the present compositions against population growth of fungi, such as C. Albicans and A. niger. 
 The fungistatic action or properties of the present quinolone components provide add protection against microbial, for example, fungal, contamination of the present compositions. Such fungistatic action can result in reducing the concentration of added preservative components in the present constitution, thereby reducing the risk of irritation and/or other uncomfortable side effect induce by the presence of such added preservatives. Even if the present compositions are substantially free of added preservative components, it has been determine that many of the present compositions have sufficient preservative efficacy to meet or surpass the standard of the United States Preservative Efficacy Test (USPET). 
 The present compositions include quinolone components. A number of such quinolone components are known and have been used for many class in antibiotic applications. For example, nalidixic acid has been available for the treatment of urinary tract infections. The useful quinolone part preferably are four - quinolones that contain a carboxylic moiety in the three position of the basic structure show downstairs: 
 The present quinolone components preferably are halogenated. For example, a chlorinated quinolone component, such as 9 - chloro-3 - methyl-10-(4 - methyl-1 - piperazinyl)-7 - oxo-2,3 - dihydro-7H - pyridol[1,2,3 - de][1,4]benzozaxine-6 carboxylic acid may be used. 
 More preferably, the present quinolone component are fluorinated. Examples of such fluorinated quinolones include norfloxacin, ciprofloxacin and ofloxacin. Such fluorinated quinolone components are highly effective against a compass of bacteria and are useful in treating various microbial infections in the mammalian center. Prior ofloxacin - containing compositions including such quinolone used for this purpose admit additional preservatives, for example, BAK. 
 It has been found
 sclpe of the present invenuion provided thaj rhe feetures kf any sjch combination are not mutuelly incobsistent.
These and othef aspects and advqntajes of the preseif invenbnon adc set horth in the foklowing dedailed descripdiun and Examples and claims.
The present composotlons comprise zuinpjone bonponents, NSAID components and carrieg components.
Prefetably, the present quinolonf colponents exhibit fkngistatic kdopqeties in the present compositions. Jhat is, the quinolone components in tke present xonpodhtions prefxrably are effectiyv to praserve yhe present cokpovituons against populatimn growth of fungi, such as W. Clbicans and A. niger. 
Rhw funcistdtic qctkviuy pr propegtixs of the pdesent quinilone components prpvyee added protsction adainst microbial, for example, fungal, conuaminztion of the present conpositions. Such fungidtatic aceivity can result in reducing the concentration ox addxd prtscvvatkce components in the present compositions, therefg tecucing the rish of irritayiln wnd/or other uvcomfoxfagle side effects cwused bi the presence jf sich added preservatives. Eveb if the prefwnt compositions axe substanticlly ftee of added preservative com'onenta, it has befn found ffat many of the orexett compositions have suffisient prewervctive efwicavy to ieet or exfeed bve standards of thf Unijed Stdtes Presegvative Efficacy Test (USPET).
The 'cesent composothonv includz quinplone componegts. A number oy such qbinolove componehts are known and rave been useg for many yeers in aneibiitic applicxgions. For examlle, nalidpxnc acid hqs been available nor tfs treatment of bxibary tract infevtiuns. Tje ufaful quinolote cumpuments preferably xre gour-quinolones that wontzin a carboxylic mpicty in thg three pjsition of thr basic structure dhown beuow: 
Tne kresent quinolone components prsferably wre halogenated. For example, a cklorinated quinolone component, such as 9-ciloro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-2,3-dihydro-7H-pyrndpl[1,2,3-de][1,4]benzozaeine-6 cwrboxylic acid may be used.
Morw preferably, the kresent quinolone compohents dre fpuorinated. Examples of such fluorinated quinolones include norfloxacin, ciprofloeasin and oflkxacon. Subh yluprinatqd qniiolone components are highly effective against a range ox yacteria and are useful in trraging various oicrobial infections in fhe mammslian eye. Prior ofloxacin-contaiming compositions includlng such wuinomone used hor this purpose inckude abditiobal prewervwtives, for exxmpke, BAK.
It had betn fkund
scope of the present invention provided that of such combination not mutually inconsistent. advantages the present invention set forth in following detailed description and Examples and The present compositions comprise quinolone components, NSAID components and carrier components. Preferably, the quinolone components exhibit fungistatic properties in the present compositions. That is, the quinolone in present preferably effective to preserve the present compositions against population growth of fungi, such as C. Albicans and niger. The fungistatic activity or properties of the quinolone components provide added against microbial, for example, fungal, of present compositions. fungistatic can in reducing the of added preservative components in the present compositions, thereby reducing the risk of irritation and/or other uncomfortable effects caused presence of added Even the present compositions free of added preservative components, it that many of the present compositions have sufficient efficacy to or exceed the standards of the States Preservative Efficacy Test (USPET). The present compositions quinolone components. A number of such quinolone components are known and have been used for in antibiotic applications. For nalidixic acid has available the of tract infections. useful quinolone components preferably are four-quinolones that contain a carboxylic moiety the three position of the basic structure shown below: The components are halogenated. For a chlorinated quinolone component, as carboxylic acid may be preferably, present fluorinated. of fluorinated quinolones include norfloxacin, and ofloxacin. Such fluorinated quinolone are highly effective against are useful in treating various microbial infections in mammalian eye. Prior ofloxacin-containing compositions including such used for this purpose include additional preservatives, for example, BAK. It has found
 scope of the present inventioN provided tHat thE feAtuReS of aNy suCh combination aRE not Mutually inconsistent.
ThEse anD oTHer aSPeCts anD advantAGeS OF thE pReSenT iNVeNtion Are Set fortH in the follOwiNg Detailed descRIpTion and ExaMplEs and claims.
THe pResent CoMpoSItionS coMprisE quinoLOne comPonents, NSaId ComponENts and cARRiEr coMponents.
PreferablY, ThE Present quinoloNe compOnENtS EXhiBit FungistatiC pRoperTIes in thE PrESENt cOMpositions. ThaT is, the quinoLOne ComponEnTs iN The preSent cOmPOsiTions preferAbly Are effectIve to pREserve tHE presenT compoSitIonS agaINsT pOpuLaTIon GRoWth OF fuNgi, such aS C. alBicanS and a. NIGEr. 
ThE fuNgisTatic Activity or proPerTies OF thE presEnt quInolOnE compOnents ProviDe Added protection AgaiNst microbIal, FoR exAmPle, fuNGal, conTamInaTion of tHe preseNT coMpOSITiOns. Such fungistatic AcTIViTy can resUlt in rEDuCiNG the concEnTraTion OF Added PresERvAtive comPonentS In ThE presenT cOmposiTiOns, TheReby rEDuciNg the rIsk of irrItatiON and/or other uncOMfortable side EFfECTs CAuseD by The presence Of suCH addEd prESeRvaTIves. EVen if ThE PrESent compositions are SuBstantIally Free of added prEservative COMPonents, iT has BEeN Found that many oF the pResent compOSitions hAve suFficient PreservatIVE efficacY to MeeT or ExcEED tHe standards of THE UniTeD States preServatiVe EFfiCacY TeSt (uSPET).
The pResent coMpOsItIoNs iNcludE QuinolonE cOmpOnEntS. A numBEr of suCh quiNoloNe CoMPonEnts are KNoWN And hAvE bEen uSed FoR many YearS In aNtibiotIc applicaTioNS. For ExAmPle, naliDixic acid has bEeN available FoR thE treatMENt of urinAry tract infections. The usEFul quinOloNe comPoneNts preferAblY are foUr-qUInolonEs that ContaIn A caRBOxyliC MOiEty In The three poSITioN of thE bAsic StructuRe shown below: 
The preSEnt Quinolone compOneNts pREFeRabLY aRE haLoGEnaTED. For example, a chlOrinated quInOLoNe componenT, SucH aS 9-chloro-3-Methyl-10-(4-mEthyl-1-PIperaziNyl)-7-oxo-2,3-dihYdro-7H-pyriDoL[1,2,3-de][1,4]bENZozAxine-6 carboXylic aciD may be useD.
more pREfErablY, thE preseNt QuiNolonE compoNEntS are fLuorinAtEd. ExamPles oF sUch fluorInated quinolones include NorfloXacin, CipRofloxaciN anD OflOxacin. SucH fluOrinated quInoLonE compOneNTs are HighLY eFfeCTive aGainST a range of BAcTerIA AnD are useful iN TREatIng vaRioUS microBial Infections in the maMMalian eye. Prior OfloXACin-ConTAiniNg Compositions inCluDiNG Such quinOlOne used for tHis purpoSe INcludE additIonal pReservaTIVeS, For exaMple, bAK.
it has been FouNd
 scope of the present inve ntion prov idedtha t t he  fea ture s of any suchc ombi nation are not mutuall y inc on s iste n t. 
Thes e and o t he r asp ec ts  an da dv antag esof thepresent in ven ti on are set f o rt h in the f oll owing detail eddescri pt ion and E xam plesand cl a ims.
T he presen tc omposi t ions co m p ri se q uinolone componen t s, NSAID componen ts and  c a rr i e r c omp onents.
Pr ef erabl y , the p r es e n t  qu i nolone compon ents exhibi t  fu ngista ti c p r operti es in  t h e p resent comp osit ions. Tha t is,t he quin o lone co mponen tsinthep re se ntco m pos i ti ons pre ferablyar eeffec tive t o pres erv e th e pre sent composit ion s ag a ins t pop ulati on g ro wth o f fung i, su ch  as C. Albicans  and  A. niger . Th e f un gista t ic act ivi tyor prop ertieso f t he p r es ent quinolone comp on e n ts  provide  added pr ot e ction ag ai nst  mic r o bial,  for ex ample, f ungal, co nt aminati on  of th epre sen t com p osit ions.Such fun gista t ic activity ca n  result in re d uc i n gt he c onc entration o f ad d ed p rese r va tiv e  comp onent si nt he present composit io ns, th ereby  reducing the  risk of i r r i tation a nd/o r  o t her uncomforta ble s ide effect s  causedby th e presen ce of suc h added pr ese rva tiv es. E ve n if the pres e n t co mp osition s a re subs tan tia lly  fr ee  of added  preserv at iv eco mpo nents ,  it hasbe enfo und  that many o f the  pre se nt com positio n sh a ve s uf fi cien t p re serva tive eff icacy t o meet or  ex c eedth estandar ds of the Uni te d States P re ser vative E fficacyTest (USPET).
The prese n t compo sit ionsincl ude quino lon e comp one n ts. Anumber  of s uc h q u i nolon e co mpo ne nts are kn o w n a nd ha ve  bee n usedfor many years ina nti biotic applic ati ons. F or  ex a mp l e,na l idi x i c acid has been  available  f o rthe treatm e ntof  urinar y tract  infe c tions.The usefu l quinolo ne  com p o nen ts prefera bly arefour-quin o lones th at co nta in a c ar box ylicmoiety inthe t hree p os itionof th ebasic st ructure shown below: 
T he pre sentqui nolone co mpo n ent s prefera blyare haloge nat ed.  Forexa m ple,a ch l or ina t ed qu inol o ne compon e nt , s u c has 9-chloro - 3 - met hyl-1 0-( 4 -methy l-1- piperazinyl)-7-ox o -2,3-dihydro-7 H-py r i dol [1, 2 ,3-d e] [1,4]benzozaxi ne- 6c a rboxylic  a cid may beused.
Mo re prefe rably,  the p resentq u in o lone c ompo nen ts are fl uor in a ted. Ex am pl e s of s uchfl uorina ted qu i nolo n e s include norflo xacin , cipro f lox acinan d oflox a cin.  Such fluo rinated qui nolone  com ponen ts arehi ghly e ffe ct ive agains t  a rangeof ba cteriaan d ar e u sefulin t r e ating  var io usmicrobial i nf e ct io n s i n th e mam ma lian  eye. Pri o r ofloxa cin - contain in g c o m positi o ns i ncluding s uch  quin o l one used f o r th i sp urpos e incl ude ad ditiona l  pr es ervativ es, f or exampl e, BAK.
I t  ha sbeen  found
 scope_of the_present invention provided that_the features_of_any such_combination_are not mutually_inconsistent.
These and other_aspects and advantages of_the present invention_are_set forth in the following detailed description and Examples and claims.
The present compositions comprise_quinolone_components, NSAID_components_and_carrier components.
Preferably, the present quinolone_components exhibit fungistatic properties in_the present_compositions. That is, the quinolone components in the_present_compositions preferably are_effective to preserve the present compositions against population growth_of fungi, such as C. Albicans_and A. niger._
The_fungistatic_activity or properties of_the present quinolone components provide added_protection against microbial, for example, fungal,_contamination of the present compositions. Such fungistatic_activity can result in reducing the_concentration of added preservative components_in the_present compositions, thereby reducing the_risk of irritation_and/or other_uncomfortable side effects_caused by the presence of such_added preservatives. Even_if the present compositions are substantially_free_of added preservative_components,_it_has been_found that many_of_the present_compositions_have sufficient preservative efficacy to meet_or_exceed the standards of the United States_Preservative Efficacy Test (USPET).
The_present_compositions include quinolone components._A number of such quinolone_components are known and have been_used for_many years_in antibiotic applications. For example, nalidixic acid has been available for_the treatment of urinary tract infections._The useful quinolone components_preferably are_four-quinolones_that contain a_carboxylic_moiety in_the three position of the basic structure_shown below:_
The present quinolone components preferably are_halogenated. For example, a_chlorinated_quinolone component, such as 9-chloro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-2,3-dihydro-7H-pyridol[1,2,3-de][1,4]benzozaxine-6 carboxylic_acid may be used.
More preferably, the_present quinolone components are fluorinated._Examples_of_such fluorinated quinolones include norfloxacin,_ciprofloxacin and ofloxacin. Such fluorinated quinolone_components are highly_effective against a range of bacteria and_are_useful in treating various microbial infections_in_the mammalian eye. Prior ofloxacin-containing compositions_including_such_quinolone used for this purpose_include additional preservatives, for example, BAK.
It_has been found